LUXA BIO Announces First Participant Dosed in Phase 1/2a Clinical Trial of Adult RPESC-RPE-4W for Dry Age-related Macular Degeneration
FORT LEE, N.J.--(BUSINESS WIRE)--Luxa Biotechnology (LuxaBio), a joint venture between Y2 Solution Co. Ltd, Seoul,…